… As reported recently, critically ill COVID‐19 patients show genetic polymorphisms in one
IFN receptor gene (IFNRA2) and in a gene locus near the Janus kinase (JAK) TYK2, which is …

… the uncertain impact of patient or disease-related risk factors for VTE. A safety trial of tofacitinib
… with one cardiovascular risk factor. An interim analysis reported an increased risk of VTE …

… of predisposing conditions and risk factors for VTE. In addition to the known risk factors that
can … Greater VTE risk is noted in patients with chronic inflammatory conditions, particularly RA …

… of VTE remained increased in patients with RA after adjusting for known thromboembolic
risk factors (hazard ratio [HR] 1.4; 95% confidence interval [CI] 1.1–1.7). A recent meta-analysis …

… of AESIs, especially in patients who do not display CV risk factors at baseline. Our study
could not identify differences between JAKis. Different safety profiles should be defined in larger …

… In specific patient populations with risk factors for or prior history of MACE or VTE, the risk
of subsequent MACE or VTE with tofacitinib use is considerably heightened. Post-hoc …

… age, the mean (standard deviation) number of risk factors were 3 (1.4), and … risk factors in
addition to their age. In conclusion, risk factors that may impact treatment with oral Janus kinase …

… with cardiovascular risk factors. Hence, the benefits of treatment and … risks for adverse
events when positioning therapies is critical. Younger patients with no cardiovascular risk factors …

… risk associated with anti-JAKs, and on the need for accurate evaluation of host-related
risk factors in high risk … A new class of synthetic oral drugs inhibiting the Janus Kinases (JAKs) …

… and MS, along with their modifiable risk factors, our findings will advance innovations in … 1
is associated with multiple comorbidities and risk factors that can increase susceptibility and/or …